Moors & Cabot Inc. Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Moors & Cabot Inc. increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 18.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,469 shares of the company’s stock after buying an additional 8,390 shares during the quarter. Moors & Cabot Inc.’s holdings in Moderna were worth $3,640,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in MRNA. O Shaughnessy Asset Management LLC raised its holdings in shares of Moderna by 40.8% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 10,869 shares of the company’s stock valued at $1,158,000 after purchasing an additional 3,148 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of Moderna by 307.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 13,158 shares of the company’s stock worth $1,402,000 after purchasing an additional 9,931 shares during the period. Bessemer Group Inc. grew its holdings in Moderna by 4.0% in the 1st quarter. Bessemer Group Inc. now owns 7,258 shares of the company’s stock valued at $774,000 after buying an additional 276 shares during the period. Lake Street Advisors Group LLC acquired a new position in shares of Moderna in the 1st quarter valued at $398,000. Finally, Crewe Advisors LLC purchased a new stake in shares of Moderna during the 1st quarter worth about $167,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 0.1 %

NASDAQ MRNA traded up $0.04 during mid-day trading on Wednesday, reaching $37.33. 1,421,693 shares of the stock were exchanged, compared to its average volume of 4,755,108. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market cap of $14.37 billion, a P/E ratio of -6.41 and a beta of 1.69. The stock has a 50 day simple moving average of $56.98 and a 200-day simple moving average of $95.46. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.39) earnings per share. On average, analysts anticipate that Moderna, Inc. will post -9.43 EPS for the current year.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 2,930 shares of company stock worth $217,170. 15.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on MRNA shares. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, Berenberg Bank started coverage on Moderna in a research report on Tuesday. They issued a “hold” rating and a $42.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $84.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.